FDA Advisory Committee: ..... YES!

Thank you!

In a step forward for symptomatic treatment in MS, the FDA Advisory Committee today said "yes" to Acorda's (ACOR) NDA application.

This is a very good sign and I would be surprised if the FDA in its October 22nd meeting says "no." The only thing that may prevent this final decision, is the suggestion that Acorda should study even lower doses of the medication (as the lowest dose studied is the one that they are choosing, so we don't know what would happen with an even lower dose).

Let's hope the FDA says those studies can happen after the approval. I, for one, would be happy to conduct this type of post-marketing study.

I guess, everything is a little unusual nowadays.

- Dr. Daniel Kantor, MD BSE
Medical Director
Neurologique

info@neurologique.org
www.neurologique.org